GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

BAE Systems also came under pressure, falling 24p to 1797p despite its upgrade to 2025 guidance. GSK also surrendered initial ...

GSK stock rose 2.3%, closing at 39.85. Shares are trading above their 50-day and 200-day moving averages in lengthy consolidation with an entry at 45.92, according to MarketSurge.

GSK Stock Performance GSK stock opened at $38.66 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87.

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma therapy approval.

GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile of the Blenrep (belantamab mafodotin-blmf) combination therapy at the ...

GSK (GSK) stock gains as FDA broadens the label for the company's asthma therapy Nucala l for COPD with an eosinophilic phenotype. Read more here.

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...